Clinical Trial

Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
An open-label, randomized, single-center, dose ascending trial will be conducted to evaluate the efficacy and safety of sublingual oxytocin for the prevention of post-partum hemorrhage caused by uterine atony in term pregnant women having an uncomplicated vaginal delivery.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-05.
Trial Details
NCT Number NCT06968481
Lead Sponsor Insud Pharma
Conditions Post Partum Hemorrhage
Enrollment 330 participants
Start Date 2026-05-30
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-23